

CID16020046, GPR55 antagonist

Catalog	Unit
TBI5362-5MG	5 mg
TBI5362-25MG	25 mg

Product Details

Formal Name: 4-[4,6-Dihydro-4-(3-hydroxyphenyl)-3-(4-methylphenyl)-6-oxopyrrolo[3,4-c]pyrazol-5(1H)-yl]benzoic acid

Molecular Formula: C₂₅H₁₉N₃O₄

Formula Weight: 425.4

CAS Number: 834903-43-4


Purity: >98%

Formulation: Powder

Solubility: Soluble in DMSO (45 mg/ml)

Storage: -20°C

Stability: ≥ 2 years.



Applications

GPR55 antagonist

Functions

Selective GPR55 antagonist. In HEK293 cells expressing GPR55, the compound behaves as an antagonist on lysophosphatidylinositol (LPI)-mediated Ca²⁺ release but was inactive on cells expressing CB1 and CB2. It blocks LPI-induced migration of colon cancer cells. It displays protective effects against oxidized LDL-induced inflammation, mitigates advanced glycation end products-induced chondrocyte activation, and displays anti-inflammatory effects in various cells. A useful tool for studying the role of GPR55 in cellular physiology.

Application Procedures

First dissolved in Soluble in DMSO (45 mg/ml), then diluted to aqueous buffer. Solutions in DMSO may be stored at -20°C for up to 3 months.

For research use only.